PEG-Conjugated Local Anesthetic Sustained Release System
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current local anesthetics used for non-anesthetic analgesia have short-acting effects, require frequent administration, and are associated with significant adverse reactions, making them inconvenient and risky for patients, especially for chronic pain management.
Innovation Solution
A conjugate of polyethylene glycol (PEG) with a local anesthetic, such as bupivacaine, is developed to create a sustained release system that maintains effective analgesic concentrations for extended periods, reducing adverse reactions and the frequency of administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If local anesthetics are administered frequently to maintain analgesic effect, then pain relief duration is improved, but patient compliance deteriorates due to inconvenience and risk of adverse reactions
Solution Approach 1:
The patent applies sustained-release technology to local anesthetics, creating a continuous release system that maintains therapeutic drug levels over extended periods (up to 72 hours or longer). This eliminates the need for frequent re-administration while maintaining consistent analgesic effect, directly resolving the contradiction between duration of action and patient compliance
Solution Approach 2:
The patent modifies the release kinetics parameter of local anesthetics by using sustained-release formulations, changing the drug delivery profile from rapid short-acting release to slow prolonged release. This parameter change extends the effective duration while reducing administration frequency, thereby improving patient compliance
2Duration of action of moving object
If high dose of local anesthetic is used to extend analgesia duration, then pain relief duration is improved, but severity of adverse reactions worsens
Solution Approach 1:
By implementing sustained-release mechanisms, the patent maintains continuous low-to-moderate dose delivery of local anesthetics over extended periods rather than administering high doses intermittently. This continuous low-level exposure achieves prolonged analgesia while keeping drug concentrations below toxic thresholds, resolving the contradiction between duration extension and adverse reaction severity
Solution Approach 2:
The patent uses moderate doses of local anesthetics delivered continuously over time rather than excessive high doses given intermittently. This partial action approach maintains therapeutic efficacy for pain relief while avoiding the toxic effects associated with high peak concentrations, thereby extending duration without increasing adverse reaction severity
3Object-affected harmful factors
If local anesthetic dosage is reduced to minimize adverse reactions, then severity of adverse reactions is improved, but analgesic effect duration worsens
Solution Approach 1:
The sustained-release formulation transforms short-acting low-dose administration into long-acting continuous low-dose delivery. This maintains drug concentrations within the therapeutic window for extended periods (72 hours or more), simultaneously achieving reduced adverse reactions through lower doses and extended duration through continuous release
Solution Approach 2:
The patent changes the release rate parameter of the local anesthetic to achieve slow, prolonged release. This kinetic parameter modification allows low doses to produce extended analgesic effects by maintaining therapeutic levels over time, resolving the contradiction between reducing adverse reactions and maintaining adequate duration
4Reliability
If frequent administration of local anesthetic is required, then analgesic effect is maintained, but patient compliance deteriorates due to inconvenience
Solution Approach 1:
The sustained-release system provides continuous drug delivery over 72 hours or longer, maintaining reliable analgesic effect without requiring frequent patient intervention. This single or infrequent administration achieves consistent pain control, simultaneously ensuring effect reliability and improving patient compliance by eliminating frequent dosing routines
Data Source
AI summary
The invention discloses use of a conjugate of polyethylene glycol and a local anesthetic in non-anesthetic analgesia. A local anesthetic is prepared into a prodrug or a sustained release preparation, wherein a high molecular polymer such as polyethylene glycol in the prodrug is covalently bonded with a local anesthetic, and auxiliary materials with a sustained release effect in the sustained release preparation are non-covalently bonded to the local anesthetic. After administration, there is no anesthesia and analgesic effect before the release of the free local anesthetic. After the free local anesthetic is released, an analgesic effect is achieved. And the prodrug or the sustained-release preparation of the local anesthetic of the present invention releases the drug slowly, and renders the drug concentration kept stable and long-lasting in the effective concentration range of non-narcotic analgesia, and the long-acting non-anesthetic analgesic effect can be achieved while significantly reducing the clinical adverse reactions of local anesthetics and reducing the number of administrations. The effectiveness of the drug is greatly enhanced and the clinical application range of local anesthetics is expanded.